Free Shipping Over $150+
GLP-2 TZ (50mg)
$179.99
Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide used in metabolic and incretin research. Lyophilized powder for laboratory research use only.
We Accept:
Certificate of Analysis
DOWNLOAD
Independently Verified. Every Batch
Every Aurevena product is sent to an independent, accredited third-party laboratory before it is offered for sale. Certificates of Analysis confirm compound identity, purity percentage, and the absence of harmful contaminants.
COAs are published by lot number so researchers can verify the exact product they receive. We do not sell any product that does not clear our purity threshold.
- Compound identity (HPLC / MS verification)
- Purity percentage (target ≥ 99%)
- Absence of heavy metals
- Lot-number traceability
CERTIFICATE OF ANALYSIS
GLP-2 TZ (50mg)
50mg
PURITY
99.80%%
ASSAY
50.47mg
IDENTITY
Confirmed
HEAVY METALS
<20 ppb
TAMC
0 CFU
TYMC
0 CFU
- Description
- Compound Info
- Research Overview
Description
Tirzepatide is a dual-agonist peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, making it a valuable tool compound for incretin and metabolic research. In laboratory settings it is studied for its combined receptor pharmacology, insulin-secretion signaling, energy-balance pathways, and glucose-regulation mechanisms. Supplied for in-vitro and laboratory research only — not for human or veterinary use.
| Compound Class | Synthetic 39-amino acid dual GIP/GLP-1 receptor agonist (acylated) |
|---|---|
| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.45 g/mol |
| Sequence | 39-amino acid peptide acylated at Lys20 with a C20 fatty diacid via a γGlu-AEEA-AEEA linker; full sequence in public chemical databases (PubChem CID 156588324). |
| Appearance | White to off-white lyophilized powder |
Research Overview
Used in in vitro and preclinical research relating to GIP and GLP-1 receptor chemistry and incretin signaling studies.
Storage
Store unreconstituted vials refrigerated at 2-8°C and long-term at -20°C; once reconstituted, store at 2-8°C and use within 30 days.
IMPORTANT RESEARCH NOTICE
Not for human consumption.
This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease. All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims. By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
Frequently Asked Questions
How should I store my peptides?
Lyophilized (powder) peptides should be stored at -20°C for long-term storage or 2-8°C (refrigerator) for short-term. Always protect from light and avoid repeated freeze-thaw cycles.
What is your return policy?
We offer damage protection on every order. If your product arrives damaged in transit, contact us with photos for a one-time replacement. All claims require photo evidence and are subject to review. One replacement per customer per order. Reconstituted products are not eligible. We do not offer refunds for change of mind or misuse.
Are your peptides third-party tested?
Yes, every batch is tested by independent, accredited U.S. laboratories for purity verification and Mass Spectrometry for identity confirmation. Test results are published on each product page as Certificates of Analysis (CoA).
How long does shipping take?
Orders are processed within 1-2 business days. Standard shipping typically arrives within 3-5 business days from fulfillment. Express and overnight options are available at checkout. Every order includes free shipment protection.
Do you ship internationally?
Currently, we ship within the United States only. We're working on expanding our shipping capabilities to serve researchers worldwide.
Can I modify or cancel my order?
Orders can be modified or canceled within 5 min of placement. After this window, orders enter processing and cannot be changed. Contact hello@aurevenaresearch.com immediately if you need to make changes.
What should I do if my item arrives damaged?
We offer damage protection on every order. If your product arrives damaged in transit, contact us with photos for a one-time replacement. All claims require photo evidence and are subject to review. One replacement per customer per order. Reconstituted products are not eligible. We do not offer refunds for change of mind or misuse.
Recently Viewed
Sources & References
Peer-reviewed research
Cardiovasc Diabetol
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction
Research FAQ
Compound and research-use information
What is GLP-2 TZ?
GLP-2 TZ is a synthetic peptide research compound designed as a dual agonist of the GIP and GLP-1 receptors. It is supplied strictly for laboratory research use.
What is GLP-2 TZ studied for in the research setting?
GLP-2 TZ is used in vitro and in preclinical research as a reference dual GIP / GLP-1 receptor agonist to study incretin-receptor binding and downstream signaling in cell and animal metabolic models. It is a mechanistic research tool only.
What form is Aurevena's GLP-2 TZ supplied in?
GLP-2 TZ is supplied as a lyophilized (freeze-dried) powder. Every batch is tested by independent, accredited U.S. laboratories for purity and identity, with the Certificate of Analysis published on this product page. Store lyophilized peptide cold and protected from light, and avoid repeated freeze-thaw cycles.
Is GLP-2 TZ intended for human use?
No. GLP-2 TZ is sold by Aurevena strictly for laboratory and research use only. It is not a drug, dietary supplement, cosmetic, or medical device, and is not intended for human or veterinary use, consumption, or for the diagnosis, treatment, cure, or prevention of any disease.
